Drugs / Navocaftor
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT05538585 | Sep → Dec 2022 | — | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT05530278 | Sep → Nov 2022 | — | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT03589313 | Feb → Mar 2018 | cystic fibrosis | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT03128606 | Mar 2017 → Feb 2018 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04853368 | Sep 2021 → Jun 2023 | cystic fibrosis | AbbVie | Terminated | Mixed Stop: Business |
| Phase 2 | NCT03969888 | Dec 2019 → Jun 2022 | cystic fibrosis | AbbVie | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-03-22 | Lakefront Biotherapeutics NV | Galapagos initiates Phase 1 study with novel CF potentiator GLPG3067 lakefrontbio.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Navocaftor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05530278 ↗ |
| Known as | ABBV-3067 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03969888 ↗ |
| Known as | GLPG3067 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03128606 ↗ |
| Action | Activate | “Cystic fibrosis transmembrane conductance regulator positive modulator” CHEMBL4802150 ↗ |
| Modality | Small molecule | — CHEMBL4802150 ↗ |
| Route | Oral | “GLPG3067 oral suspension, single ascending doses, daily” NCT03128606 ↗ |
| Target | CFTR | “Cystic fibrosis transmembrane conductance regulator positive modulator” CHEMBL4802150 ↗ |